

A

GRAYCARY TECHNOLOGY'S LEGAL EDGESM

4365 Executive Drive, Suite 1600
San Diego, CA 92121-2189
www.graycary.com

D) 858-677-1456
F) 858-677-1465

03-12-01

03/08/01
jc867 U.S. PTO

March 8, 2001

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"EXPRESS MAIL" LABEL NUMBER EL 617 036 076 US
DATE OF DEPOSIT: March 8, 2001

I hereby certify that this paper is being deposited with the United States Postal Service "EXPRESS MAIL Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to BOX PATENT APPLICATION, Commissioner of Patents and Trademarks; Washington, DC 20231.

Mikhail Bayley
Mikhail Bayley

jc978 U.S. PTO
09/802779
03/08/01

BOX PATENT APPLICATION
COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Sir:

Transmitted herewith for filing is the new **continuation-in part** patent application of:

APPLICANT(s): James E. Hildreth

FOR: β -CYCLODEXTRIN COMPOSITIONS, AND USE TO PREVENT
TRANSMISSION OF SEXUALLY TRANSMITTED DISEASES

Enclosed are the following papers, including all those required to receive a filing date under 37 CFR § 1.53(b):

	<u>Number of Pages</u>
Specification	60
Claims	5
Abstract	1
Application Cover Page	1
Declaration (unsigned)	2
Drawing(s)	0

Enclosures:

Request and Certification Under 35 U.S.C. 122(b)(2)(B)(i)
Postcard

This application is a continuation-in-part of U.S. Serial No. TBA (Atty. Docket No. JHU1710-2), filed March 7, 2001, which claims priority under 35 U.S.C. § 119(e)(1) to U.S. provisional application Serial No. 60/267,199, filed February 7, 2001; and U.S. Serial No. 60/187,784, filed March 8, 2000, the contents of which is herein incorporated by reference in its entirety.

In re Application of:
James E. Hildreth
Application No.: To Be Assigned
Filed: March 8, 2001
Page 2

PATENT
Attorney Docket No.: JHU1710-3

The filing fee is calculated as follows. Small Entity status is claimed.

(1) For	(2) Number filed	(3) Number extra	(4) Large Entity Rate	(5) Small Entity Rate	(6) Calculations
Basic Filing Fee			\$ 710.00	\$355.00	\$355.00
Total Claims	45 - 20 =	25	X \$ 18.00	X \$ 9.00	\$ 225.00
Independent Claims	5 - 3 =	2	X \$ 80.00	X \$ 40.00	\$ 80.00
Multiple Dependent Claim(s) (if applicable)			\$ 270.00	\$135.00	
Total of above Calculations =					\$660.00

Please defer the payment of the filing fee until the filing of the Declaration. Please charge any other required fees, **EXCEPT FOR THE FILING FEE**, or credit any overpayments, to Deposit Account 50-1355, referencing the Attorney Docket number shown above. A copy of this transmittal letter is attached.

If this application is found to be INCOMPLETE, or if a telephone conference would otherwise be helpful, please call the undersigned at (858) 677-1456.

All future correspondence should be addressed to:


Lisa A. Haile, Ph.D.
Gray Cary Ware & Freidenrich LLP
4365 Executive Drive, Suite 1600
San Diego, CA 92121-2189
Telephone: (858) 677-1456
Facsimile: (858) 677-1465

A duplicate copy of this letter is enclosed. Kindly acknowledge receipt of this application by returning the enclosed postcard.

Respectfully submitted,

Date:

3/8/01



Lisa A. Haile, Ph.D.
Attorney for Applicant
Registration No. 38,347
Telephone: 858-677-1456
Facsimile: 858-677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1600
San Diego, CA 92121-2189
Customer Number: 28213

EXPRESS MAIL LABEL NO.: EL 617 036 076 US

PTO/SB/35 (11-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REQUEST AND CERTIFICATION
UNDER
35 U.S.C. 122(b)(2)(B)(i)**

First Named Inventor JAMES E. HILDRETH

Title

β -CYCLODEXTRIN COMPOSITIONS, AND USE TO PREVENT
TRANSMISSION OF SEXUALLY TRANSMITTED DISEASES


Atty Docket Number

JHU1710-3

I hereby certify that the invention disclosed in the attached application **has not and will not** be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).

3/8/01

Date



Signature

GRAY CARY WARE & FRIEDENRICH LLP
4365 Executive Drive, Suite 1600
San Diego, CA 92121-2189

Lisa A. Haile, Ph.D.

Reg. No. 38,347

Typed or printed name

Customer No. 28213

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).**

Burden Hour Statement: This collection of information is required by 37 CFR 1.213(a). The information is used by the public to request that an application not be published under 35 U.S.C. 122(b) (and the PTO to process that request). Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 6 minutes to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.